SWOG Cancer Research Network

Front Line post by @SWOG chairs @DrDawnHershman & @PrimoLaraMD: The Next Era of SWOG Success We see trials that are more streamlined & decentralized, that integrate community & advocate voices, that ask questions only public-powered research will answer. swog.org/news-events/ne…

We are testing the same regimen for resectable PanNETs in ⁦@SWOG⁩ 2104. Do you have the study open? 👇🏼👇🏼 Primary Tumor Size and Tumor–Vessel Interface Following Capecitabine and Temozolomide for Pancreatic Neuroendocrine pmc.ncbi.nlm.nih.gov/articles/PMC12…

How often do you have the chance to make such a huge impact on the field as a resident? The Zaidi score is based on his US NETSG🇺🇸 paper in @AnnalsofSurgery used to determine eligibility in @SWOG S2104 adjuvant CAPTEM trial for PNETs🦓 Ann Surg, 2019 vol. 270(3) pp. 422-433

Our @SWOG Chairs' blog: A Team Science Leadership Team SWOG is all about interdisciplinary collaboration and team science. We think a leadership approach with dual principal investigators who bring complementary skillsets and expertise is a great fit. swog.org/news-events/ne…

Saying Thank You: @SWOGChair Dr. Charles Blanke's last Front Line post as chair of @SWOG: "I have been honored to serve as chair of this research group over the last 13 years, and I could not be prouder of what you have accomplished in that time." swog.org/news-events/ne…

What is the biology of small cell lung cancer? What are the neuroendocrine subtypes? Can we use therapies to target the NE subtypes? @lungevity #SCLC #meded #lcsm @SclcSMASHERS @SCLCYIForum @SWOG @Annechiangmd

.@SWOG S2213 Ph3 RCT Dara-VC Induction Followed by ASCT or Dara-VCD Consolidation & Daratumumab Maintenance in Pts w/ Newly Diagnosed AL Amyloidosis [Activated: 12/1/23] swog.org/clinical-trial… #mmsm #bmtsm

Follicular lymphoma has long been deemed incurable. New findings from a 15-year follow-up analysis of clinical trial patients with follicular lymphoma could upend that prediction. @mshadman @SWOG @UR_Med. Read more: bit.ly/4rIb59x

SWOG S1602: A phase III randomized trial to evaluate BCG strain differences and priming with intradermal BCG before intravesical therapy for BCG-naïve high-grade #NMIBC. Presentation by Robert Svatek, MD @UTHealthSA. #GU26 written coverage by @RKSayyid @UAUrology > bit.ly/4bgpGTM @ASCO @SWOG

Finally, a clinical trial I’ve been working on for 2 years w/ @PBarataMD @drulkav @montypal @BrianShuch & many others @SWOG opens for enrollment very, very soon, and I couldn’t be more excited. S2419 (BIOFRONT) will be the first SWOG trial and the first phase III trial anywhere

@SWOG patient advocate Darrell Nakagawa & I are grateful to be here supporting our GU cmte as #patientadvocates for #kidneycancer & #BladderCancer. Thank you @SupportingSWOG for making it possible! Representing the pt voice helps us develop better trials & improve outcomes! #GU26

This work highlights the power of @SWOG and @theNCI cooperative group trials, along with the outstanding @swog statistical team (Michael LeBlanc and Hongli Li) at @fredhutch

15-year results from @SWOG S0016 trial suggest follicular lymphoma is curable. Cure modeling estimates a 42% cure rate among S0016 patients. Relapse rates drop markedly over time. Study is in Feb 26 @JAMAOnc @DrJFriedberg @mshadman @WilmotCancer @FredHutch swog.org/news-events/ne…

Our 15 year follow-up of @SWOG 0016 trial demonstrates that over one third of patients with advanced stage follicular lymphoma are cured with standard therapy. jamanetwork.com/journals/jamao…

Registration is open for SWOG's spring group meeting, April 30-May 2, in San Francisco! Incoming Group Chairs Drs. Primo Lara, Jr., & Dawn Hershman invite SWOG members to bring questions, concerns, & ideas to an interactive Friday plenary. Learn more at swog.org/news-events/sw…

.@SWOG S2213 Ph3 RCT Dara-VC Induction Followed by ASCT or Dara-VCD Consolidation & Daratumumab Maintenance in Pts w/ Newly Diagnosed AL Amyloidosis [Activated: 12/1/23] swog.org/clinical-trial… #mmsm #bmtsm

Ab#507 @ASCO #GU26 by #AliMoradi👉bit.ly/4tTeyDA👉Long-term outcomes w/ live bacteria (CBM588) in mRCC #kidneycancer👉addition of CBM588 to frontline ICI Rx👉⬆️ORR & PFS👉supporting upcoming Ph3 @SWOG BIOFRONT study👇 @montypal @OncoAlert @urotoday @KidneyCAN

Beautiful work from @cvulsteke et al (incl @shilpaonc #MattGalsky @y_loriot & so many other friends!). Don't forget to check out the terrific commentary from @SWOG superstars @Parminder1699 @MayoCancerCare & @slernerbcmedu1 @bcmhouston. Fully agree that #KN905 "opens a new chapter in the management of bladder cancer"!

.@SWOG S2213 Ph3 RCT Dara-VC Induction Followed by ASCT or Dara-VCD Consolidation & Daratumumab Maintenance in Pts w/ Newly Diagnosed AL Amyloidosis [Activated: 12/1/23] swog.org/clinical-trial… #mmsm #bmtsm

Terrific to have @sokolova_mdon our @SWOG #SLAI call discussing #SWOG/@CDNCancerTrials-PR26 ("TRIPLE-SWITCH") - representation from #Chile, #Uruguay, #Mexico & other sites on the call! @Nora_Sobrevilla @ReginaBarCar @TDorffOnc @MichaelOng_MD